Shan Zhuang, Yong-Mei Jian, Yong-Ning Sun, Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
World J Gastroenterol. 2017 Jun 21;23(23):4233-4242. doi: 10.3748/wjg.v23.i23.4233.
To investigate the inhibitory effect of Liuwei Dihuang Pill (LDP) on gastric tumorigenesis induced by N-methyl-N-nitrosourea (MNU) in diabetic mice.
Four-week-old mice were divided into four groups: A, 12 db/m mice treated with MNU and saline, as the non-diabetic control; B, 12 db/db mice treated with MNU and saline, as the diabetic control; C, 12 db/db mice treated with MNU and metformin, as the positive control; and D, 12 db/db mice treated with MNU and LDP. MNU was administrated for 20 wk to induce gastric carcinogenesis. LDP was administrated for 10 wk for improvement of insulin resistance. Body weight and food intake were measured every week. Blood samples were collected for assays of fasting blood glucose, insulin, insulin-like growth factor (IGF)-1, adiponectin and leptin. Stomach tissues were collected for histopathological analysis, immunohistochemical staining of Ki67, quantitative reverse transcription-polymerase chain reaction and western blotting.
The incidence of MNU-induced gastric dysplasia was significantly elevated in diabetic (db/db) mice relative to the control (db/m) mice. The incidence of gastric dysplasia was significantly reduced by LDP with suppression of cell proliferation, as demonstrated by a decrease in Ki67 staining. Hyperglycemia, hyperinsulinemia and serum IGF-1 were inhibited by LDP. Expression of IGF-1 and insulin receptor mRNAs was decreased, phosphorylation of IGF-1 receptor and AKT protein was reduced in the stomach tissues by LDP. In addition, adiponectin was increased and leptin was decreased in the serum by LDP.
LDP decreased risk of gastric dysplasia in type 2 diabetic mice by down-regulation of IGF and insulin activity and correction of adipokines disorders.
研究六味地黄丸(LDP)对糖尿病小鼠 N-甲基-N-亚硝基脲(MNU)诱导的胃癌发生的抑制作用。
将 4 周龄小鼠分为四组:A 组,12 db/m 小鼠用 MNU 和生理盐水处理,作为非糖尿病对照;B 组,12 db/db 小鼠用 MNU 和生理盐水处理,作为糖尿病对照;C 组,12 db/db 小鼠用 MNU 和二甲双胍处理,作为阳性对照;D 组,12 db/db 小鼠用 MNU 和 LDP 处理。用 MNU 处理 20 周诱导胃癌发生。用 LDP 处理 10 周改善胰岛素抵抗。每周测量体重和食物摄入量。收集血液样本进行空腹血糖、胰岛素、胰岛素样生长因子(IGF)-1、脂联素和瘦素检测。收集胃组织进行组织病理学分析、Ki67 免疫组化染色、定量逆转录-聚合酶链反应和 Western blot 分析。
与对照(db/m)小鼠相比,糖尿病(db/db)小鼠 MNU 诱导的胃发育不良发生率显著升高。LDP 可通过抑制细胞增殖降低胃发育不良的发生率,Ki67 染色减少。LDP 抑制高血糖、高胰岛素血症和血清 IGF-1。LDP 降低胃组织中 IGF-1 和胰岛素受体 mRNA 的表达,减少 IGF-1 受体和 AKT 蛋白的磷酸化。此外,LDP 增加血清脂联素,降低瘦素。
LDP 通过下调 IGF 和胰岛素活性以及纠正脂肪因子紊乱,降低 2 型糖尿病小鼠胃发育不良的风险。